NorthWest Biotherapeutics Inc (NWBO)

[Pyrrhonian]

Okay so having orphan drug status, among other cost savings benefits, means that should a therapy be granted regulatory approval to market their product that they will have marketing exclusivity rights for that specific treatment methodology for that indication. Provenge is for castrate resistant metastatic prostate cancer (has no marketing exclusivity in GBM) and ICT-107 would have given NWBO issues with DCVax-L should they have marketed ICT-107 first, but they are far behind in development. It's also incorrect to say IMUC and DNDN have orphan drug status--a company is not granted this for all their therapies, a specific therapy is for its specific indication and treatment methodology.

I'm beginning to feel that you may just be flinging things at the wall in the hopes that something sticks ;) These are things I and others have already exhaustively examined, so just think a little more logically about it and try to disprove your own point first before you post. Thanks. And gl with your CLDX short today--you must be nervous!